Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ji-Won | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Kim, Byung Soo | - |
dc.contributor.author | Nam, Seung-Hyun | - |
dc.contributor.author | Koh, Youngil | - |
dc.contributor.author | Kwon, Ji-Hyun | - |
dc.contributor.author | Choe, Pyoeng Gyun | - |
dc.contributor.author | Park, Wan Beom | - |
dc.contributor.author | Kim, Inho | - |
dc.date.available | 2020-11-02T14:41:31Z | - |
dc.date.issued | 2015-12 | - |
dc.identifier.issn | 1386-6532 | - |
dc.identifier.issn | 1873-5967 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/7288 | - |
dc.description.abstract | Background: The incidence of herpes zoster is substantial during bortezomib treatment in patients with multiple myeloma (MM). Objectives: This study aimed to elucidate the effect of chemotherapy with or without bortezomib in MM patients on their herpes zoster incidence and varicella zoster virus (VZV)-specific cell-mediated immunity (CMI). Study design: Peripheral blood mononuclear cells were collected at baseline and after 1 month of bortezomib-based or thalidomide-based chemotherapy and then analyzed using VZV-specific interferongamma (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay. The clinical data from these patients were analyzed in relation to the ELISPOT results. Results: Of 58 patients analyzed, 39 patients received bortezomib and the other 19 patients, thalidomide. Among them, 5 patients developed herpes zoster during chemotherapy; all 5 were being treated with the bortezomib-based regimen and were not receiving prophylactic anti-viral agents. The median onset of herpes zoster was 32 days (range, 15-95 days) from the initiation of chemotherapy. Among patients who received bortezomib therapy, acyclovir prophylaxis significantly reduced the risk for herpes zoster (100-day cumulative incidence, 0% vs. 49.5%; p < 0.001). Spot-forming cell (SFC) counts in the IFN-gamma ELISPOT assay decreased from baseline after bortezomib (p = 0.011) or thalidomide (p = 0.096) treatment. Patients with baseline SFCs greater than 20/10(6) mononuclear cells exhibited significantly higher incidence of herpes zoster (100-day cumulative incidence, 34.8% vs. 0%; p = 0.040). Conclusions: Bortezomib treatment significantly reduced VZV-specific CMI, and high baseline SFC counts in patients receiving this treatment without acyclovir prophylaxis were associated with a significantly increased risk for herpes zoster. (C) 2015 Elsevier B.V. All rights reserved. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.title | Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy | - |
dc.type | Article | - |
dc.publisher.location | 네델란드 | - |
dc.identifier.doi | 10.1016/j.jcv.2015.10.018 | - |
dc.identifier.scopusid | 2-s2.0-84949449433 | - |
dc.identifier.wosid | 000367390700013 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL VIROLOGY, v.73, pp 64 - 69 | - |
dc.citation.title | JOURNAL OF CLINICAL VIROLOGY | - |
dc.citation.volume | 73 | - |
dc.citation.startPage | 64 | - |
dc.citation.endPage | 69 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.subject.keywordPlus | LOW-DOSE ACYCLOVIR | - |
dc.subject.keywordPlus | REACTIVATION | - |
dc.subject.keywordPlus | TRANSPLANTATION | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | RESPONSES | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | ASSAY | - |
dc.subject.keywordAuthor | Varicella-zoster virus | - |
dc.subject.keywordAuthor | Enzyme-linked immunospot assay | - |
dc.subject.keywordAuthor | Herpes zoster | - |
dc.subject.keywordAuthor | Multiple myeloma | - |
dc.subject.keywordAuthor | Bortezomib | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.